HR5526Referred to Committee
Biosimilar Red Tape Elimination Act
Introduced
In Committee
3
Passed One Chamber4
Passed Both5
Signed into Law119th
Congress
2025-09-19
Introduced
7
Cosponsors
HR
ⓘType
Sponsor
August Pfluger
Republican · TX · Representative
Votes with party: 98.9% (545 recorded votes)
Full profile: /officials/P000048
Source: Congress.gov · FEC
Cosponsors (7)
Members who have signed on to support this bill since introduction. Source: Congress.gov.
Latest Action
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Committee Activity
Currently in
- House Committee on Energy and CommerceReferred To · 2025-09-19
Plain-English Summary
This bill would streamline the approval process for biosimilar drugs—cheaper alternatives to expensive biologic medications—by reducing regulatory requirements and paperwork that manufacturers must complete. The goal is to get these more affordable treatment options to patients faster and make it easier for drug makers to bring them to market, which could lower costs for patients and insurance companies paying for medications like cancer treatments and arthritis drugs.
AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.
Subjects
Health
Full bill text is not yet cached locally.
Related legislation
Bills by the same sponsor or covering overlapping subjects.
- HR9106To authorize the President to award the Medal of Honor to Robert Lodge for acts of valor as a member of the Air Force during the Vietnam War.Referred to Committee · 2026-06-02
- HR8990Protect Domestic Oil and Gas Small Business Act of 2026Referred to Committee · 2026-05-21
- HR7443I&A Mission Reorientation Act of 2026Referred to Committee · 2026-05-14
- HR7022Mystic Alerts ActPassed House · 2026-04-21